BUZZ-Selecta Biosciences 因第二季度收入不及预期而下跌

Reuters
17 Aug 2023

** 药物开发商Selecta Biosciences 股价下跌1.8%至1美元

** 根据Refinitiv数据,该公司第二季度营收为520万美元,而分析师预计为680万美元。

** SELB表示,公司计划暂停对其他疗法开发的进一步投资,专注于痛风疗法的开发

** 包括盘中跌幅在内,股价今年累计下跌6.2

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10